{"entity":{"id":"nct05584800","kind":"trial","name":"Study of ZGGS18 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ZGGS18 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","summary":"Study of ZGGS18 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05584800 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 222 participants planned, started 2022-11-15 and due to reach its primary completion in 2026-11-01. Interventions recorded: ZGGS18 for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05584800","url":"https://clinicaltrials.gov/study/NCT05584800"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["zelgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05584800","phase":"1/2","setting":"A Phase I/II Dose Escalation, Tolerability, Safety, Pharmacokinetics and Multiple Cohort Expansion Study of ZGGS18 in Patients With Advanced Solid Tumors","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","enrolled":222,"outcomes":[]},"route":"/trials/nct05584800/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/"}]}}